Drug Repurposing: Progress, Challenges and Recommendations

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2018 Oct 13

PMID 30310233

Citations 1660

Authors

Sudeep Pushpakom

Francesco Iorio

Patrick A Eyers

K Jane Escott

Shirley Hopper

Andrew Wells

Andrew Doig

Tim Guilliams

Joanna Latimer

Christine McNamee

Alan Norris

Philippe Sanseau

David Cavalla

Munir Pirmohamed

Affiliations

Soon will be listed here.

Abstract

Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old' drugs to treat both common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked compounds, with potentially lower overall development costs and shorter development timelines. Various data-driven and experimental approaches have been suggested for the identification of repurposable drug candidates; however, there are also major technological and regulatory challenges that need to be addressed. In this Review, we present approaches used for drug repurposing (also known as drug repositioning), discuss the challenges faced by the repurposing community and recommend innovative ways by which these challenges could be addressed to help realize the full potential of drug repurposing.

Citing Articles

DTIAM: a unified framework for predicting drug-target interactions, binding affinities and drug mechanisms.

Lu Z, Song G, Zhu H, Lei C, Sun X, Wang K Nat Commun. 2025; 16(1):2548.

PMID: 40089473 DOI: 10.1038/s41467-025-57828-0.

Exploiting the Achilles' heel of cancer through a structure-based drug-repurposing approach and experimental validation of top drugs using the TRAP assay.

Kaur D, Chopra M, Saluja D Mol Divers. 2025; .

PMID: 40087255 DOI: 10.1007/s11030-025-11162-1.

Drug Repurposing in Pancreatic Cancer: A Multi-Stakeholder Perspective to Improve Treatment Options for Pancreatic Cancer Patients.

Hewitt E, Bouche G, Alencar A, Bigelsen S, Radu R, Stoyanova-Beninska V Cancer Manag Res. 2025; 17:429-440.

PMID: 40046652 PMC: 11881603. DOI: 10.2147/CMAR.S483151.

Old drugs, new challenges: reassigning drugs for cancer therapies.

Czechowicz P, Wiech-Walow A, Slawski J, Collawn J, Bartoszewski R Cell Mol Biol Lett. 2025; 30(1):27.

PMID: 40038587 PMC: 11881393. DOI: 10.1186/s11658-025-00710-0.

GPCR drug discovery: new agents, targets and indications.

Lorente J, Sokolov A, Ferguson G, Schioth H, Hauser A, Gloriam D Nat Rev Drug Discov. 2025; .

PMID: 40033110 DOI: 10.1038/s41573-025-01139-y.

References

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

Huang H, Zhang G, Zhou Y, Lin C, Chen S, Lin Y . Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds. Front Chem. 2018; 6:138. PMC: 5954125. DOI: 10.3389/fchem.2018.00138. View

Mittelman-Smith M, Williams H, Krajewski-Hall S, McMullen N, Rance N . Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature. Proc Natl Acad Sci U S A. 2012; 109(48):19846-51. PMC: 3511761. DOI: 10.1073/pnas.1211517109. View

Keiser M, Setola V, Irwin J, Laggner C, Abbas A, Hufeisen S . Predicting new molecular targets for known drugs. Nature. 2009; 462(7270):175-81. PMC: 2784146. DOI: 10.1038/nature08506. View

Prague J, Roberts R, Comninos A, Clarke S, Jayasena C, Nash Z . Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017; 389(10081):1809-1820. PMC: 5439024. DOI: 10.1016/S0140-6736(17)30823-1. View

Frail D, Brady M, Jane Escott K, Holt A, Sanganee H, Pangalos M . Pioneering government-sponsored drug repositioning collaborations: progress and learning. Nat Rev Drug Discov. 2015; 14(12):833-41. DOI: 10.1038/nrd4707. View

Rance N, Young 3rd W . Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology. 1991; 128(5):2239-47. DOI: 10.1210/endo-128-5-2239. View

Sloane D, Trikic M, Chu M, Lamers M, Mason C, Mueller I . Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem Biol. 2010; 5(6):563-76. DOI: 10.1021/cb100053q. View

Greene C, Krishnan A, Wong A, Ricciotti E, Zelaya R, Himmelstein D . Understanding multicellular function and disease with human tissue-specific networks. Nat Genet. 2015; 47(6):569-76. PMC: 4828725. DOI: 10.1038/ng.3259. View

10.

Tyryshkin A, Bhattacharya A, Eissa N . SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis. Cancer Res. 2014; 74(7):1996-2005. PMC: 3979529. DOI: 10.1158/0008-5472.CAN-13-1256. View

11.

Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

12.

Hennequin L, Allen J, Breed J, Curwen J, Fennell M, Green T . N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem. 2006; 49(22):6465-88. DOI: 10.1021/jm060434q. View

13.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

14.

Cudkowicz M, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D . Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014; 13(11):1083-1091. PMC: 4216315. DOI: 10.1016/S1474-4422(14)70222-4. View

15.

Wagner A, Cohen N, Kelder T, Amit U, Liebman E, Steinberg D . Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia. Mol Syst Biol. 2015; 11(3):791. PMC: 4380926. DOI: 10.15252/msb.20145486. View

16.

Kharkar P, Warrier S, Gaud R . Reverse docking: a powerful tool for drug repositioning and drug rescue. Future Med Chem. 2014; 6(3):333-42. DOI: 10.4155/fmc.13.207. View

17.

Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam R . Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006; 10(4):331-42. DOI: 10.1016/j.ccr.2006.09.006. View

18.

Jayasena C, Comninos A, Stefanopoulou E, Buckley A, Narayanaswamy S, Izzi-Engbeaya C . Neurokinin B administration induces hot flushes in women. Sci Rep. 2015; 5:8466. PMC: 4329553. DOI: 10.1038/srep08466. View

19.

Nygaard H, Wagner A, Bowen G, Good S, MacAvoy M, Strittmatter K . A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease. Alzheimers Res Ther. 2015; 7(1):35. PMC: 4396171. DOI: 10.1186/s13195-015-0119-0. View

20.

White H, Held C, Stewart R, Tarka E, Brown R, Davies R . Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014; 370(18):1702-11. DOI: 10.1056/NEJMoa1315878. View